We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Researchers Culture Novel Three-Dimensional Artificial Tumors

By LabMedica International staff writers
Posted on 07 Dec 2015
Image: This rolled-up strip of engineered tissue allows researchers to mimic the way cells grow in a tumor, yet it can be unrolled in seconds for detailed analysis (Photo courtesy of Darren Rodenhizer, University of Toronto Engineering).
Image: This rolled-up strip of engineered tissue allows researchers to mimic the way cells grow in a tumor, yet it can be unrolled in seconds for detailed analysis (Photo courtesy of Darren Rodenhizer, University of Toronto Engineering).
A team of Canadian cancer researchers has developed a novel method for growing three-dimensional cultures of cancer cells that behave as artificial tumors and which can be readily resolved to evaluate the response of individual cells to different levels of oxygen and nutrients.

The cells growing in the center of a tumor have reduced access to oxygen and nutrients as compared to those growing near the surface, nearer to blood vessels. These subtle, location-dependent environment differences influence cell behavior, but their effect has proven difficult to replicate in laboratory culture.

Investigators at the University of Toronto (ON, Canada) have reported the development of a novel culture system in the form of a rolled-up sheet that mimics the three-dimensional environment of a tumor, yet can also be taken apart in seconds.

The investigators impregnated a short strip of a porous, paper-like support material with collagen and cancer cells. The strip was then incubated for 24 hours in a nutrient-rich culture solution, which allowed the cells to adjust to their new environment. The strip was then rolled around a metal core, forming an artificial tumor, which was then cultured for several more days before performing analysis of tumor cell behavior. By unrolling the strip, the model could be rapidly disassembled for snapshot analysis, allowing spatial mapping of cell metabolism in concert with cell phenotype.

Results published in the November 23, 2015, online edition of the journal Nature Materials revealed that as the oxygen level decreased in internal areas of the tumor roll, the number of dead cells increased, which indicated that the cells had responded to the oxygen gradient.

Cells able to live under hypoxic conditions were found to behave differently than the surface cells: for example, they more strongly expressed genes associated with low oxygen conditions. Changes in gene expression, as determined by liquid chromatography tandem mass spectrometry metabolic signature analysis, were gradual and continuous along the length of the strip.

Senior author Dr. Alison McGuigan, professor of chemical engineering at the University of Toronto, said, "The technology holds great promise for the field of personalized medicine. The idea would be to take a patient's own cells and create copies of their tumor. These copies could then be subjected to various treatments and analyzed by the simple unrolling process, providing information about what is likely to work best for that specific patient. It is very translatable and transferable to other labs. We definitely want others to use it, because the larger the community, the more applications we will discover."

Related Links:
University of Toronto


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Platelet Function Analyzer
PL-12

Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more